RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Intersect Ent Stock

Intersect Ent ROE 2024

Intersect Ent ROE

2.31

Ticker

XENT

ISIN

US46071F1030

WKN

A117WV

In 2024, Intersect Ent's return on equity (ROE) was 2.31, a 0% increase from the 0 ROE in the previous year.

Intersect Ent Aktienanalyse

What does Intersect Ent do?

Intersect ENT Inc. is a biotechnology company specializing in the development of innovative therapies and devices for the treatment of chronic sinusitis and other nasal cavity disorders. The company was founded in 2003 and is headquartered in Menlo Park, California. The company's history began with the development of a novel implant system designed to provide effective and gentle treatment for chronic sinusitis. In 2012, the first product called PROPEL mini was launched, which serves as a two-part system for placement in the patient's sinuses. The implant ensures faster recovery after delicate surgeries and prevents adhesions. This innovation has revolutionized the way chronic sinusitis is treated. The PROPEL technology consists of a biodegradable polymer that gradually breaks down in the patient's body. It is available in various sizes and shapes to cater to the individual needs of each patient. In addition to the PROPEL technology, Intersect ENT also has other products in their portfolio targeting nasal cavity disorders. These include the SINUVA implant, used in patients with nasal polyps, as well as various devices for nasal perforation. Intersect ENT's business strategy is focused on maintaining and expanding their leadership in nasal healthcare innovation. The company heavily invests in research and development to create new products and technologies that meet medical needs and can improve patients' lives. To promote the sale of their products, Intersect ENT has built a comprehensive distribution network consisting of their own sales representatives and independent contract partners. The company collaborates closely with medical professionals and healthcare facilities to test and validate the effectiveness of their products. Intersect ENT is a company with a clear focus on innovation and excellence in product development. Their goal is to revolutionize the treatment of nasal diseases while providing patients with a better quality of life. With their groundbreaking technologies and extensive expertise, Intersect ENT has become a leading provider of nasal cavity solutions and is highly esteemed in the industry. Intersect Ent ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Intersect Ent's Return on Equity (ROE)

Intersect Ent's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Intersect Ent's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Intersect Ent's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Intersect Ent’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Intersect Ent stock

What is the ROE (Return on Equity) of Intersect Ent this year?

The ROE of Intersect Ent this year is 2.31 undefined.

How has the Return on Equity (ROE) of Intersect Ent developed compared to the previous year?

The ROE of Intersect Ent has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Intersect Ent?

A high ROE indicates that Intersect Ent generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Intersect Ent?

A low ROE can indicate that Intersect Ent is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Intersect Ent affect the company?

A change in ROE (Return on Equity) of Intersect Ent can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Intersect Ent?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Intersect Ent?

Some factors that can influence Intersect Ent's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Intersect Ent pay?

Over the past 12 months, Intersect Ent paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intersect Ent is expected to pay a dividend of 0 USD.

What is the dividend yield of Intersect Ent?

The current dividend yield of Intersect Ent is .

When does Intersect Ent pay dividends?

Intersect Ent pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intersect Ent?

Intersect Ent paid dividends every year for the past 0 years.

What is the dividend of Intersect Ent?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intersect Ent located?

Intersect Ent is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intersect Ent kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intersect Ent from 10/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2024.

When did Intersect Ent pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Intersect Ent in the year 2023?

In the year 2023, Intersect Ent distributed 0 USD as dividends.

In which currency does Intersect Ent pay out the dividend?

The dividends of Intersect Ent are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Intersect Ent

Our stock analysis for Intersect Ent Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intersect Ent Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.